Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY

Alnylam Pharma (ALNY) Financial Statements

1,113 Followers

Alnylam Pharma Financial Overview

Alnylam Pharma's market cap is currently ―. The company's EPS TTM is $-2.682; its P/E ratio is -88.67; Alnylam Pharma is scheduled to report earnings on August 1, 2024, and the estimated EPS forecast is $-1.05. See an overview of income statement, balance sheet, and cash flow financials.
Mar 24Dec 23Sep 23Jun 23Mar 23
Income Statement-
Total Revenue$ 494.33M$ 439.72M$ 750.53M$ 305.70M$ 319.29M
Gross Profit$ 439.72M$ 353.86M$ 671.06M$ 253.45M$ 264.42M
EBIT$ -16.97M$ -106.35M$ 181.63M$ -244.17M$ -143.41M
EBITDA$ -5.00M$ -82.38M$ 191.84M$ -233.91M$ -131.39M
Net Income Common Stockholders$ -65.94M$ -137.87M$ 157.43M$ -276.02M$ -174.10M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 2.37B$ 2.44B$ 2.41B$ 2.06B$ 2.07B
Total Assets$ 3.82B$ 3.83B$ 3.84B$ 3.40B$ 3.39B
Total Debt$ 1.30B$ 1.31B$ 1.31B$ 1.31B$ 1.32B
Net Debt$ -1.07B$ -1.13B$ -1.10B$ -743.17M$ -750.33M
Total Liabilities$ 4.04B$ 4.05B$ 4.00B$ 3.81B$ 3.65B
Stockholders Equity$ -219.27M$ -220.64M$ -165.87M$ -408.13M$ -259.24M
Cash Flow-
Free Cash Flow$ -94.49M$ -45.10M$ 342.32M$ -74.91M$ -180.37M
Operating Cash Flow$ -81.52M$ -29.80M$ 359.41M$ -58.99M$ -166.47M
Investing Cash Flow$ -67.62M$ -240.66M$ -10.76M$ -8.71M$ -76.22M
Financing Cash Flow$ 28.91M$ 39.23M$ 33.14M$ 53.39M$ 46.37M
Currency in USD

Alnylam Pharma Earnings and Revenue History

Alnylam Pharma Debt to Assets

Alnylam Pharma Cash Flow

Alnylam Pharma Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis